Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$6.27 USD

6.27
307,449

+0.19 (3.13%)

Updated May 3, 2024 04:00 PM ET

After-Market: $6.27 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Can AngioDynamics (ANGO) Pull a Surprise in Q2 Earnings?

AngioDynamics (ANGO) to gain from solid product portfolio and demand for Solero MTA system. However, unfavorable estimates are a concern.

    Why Is AngioDynamics (ANGO) Up 5.3% Since the Last Earnings Report?

    AngioDynamics (ANGO) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

      AngioDynamicis' (ANGO) Solero MTA System to Drive Growth

      Growth in the core Angiographic Catheter business is also likely to fortify the company's footprint in the global space.

        AngioDynamics (ANGO) Misses on Earnings & Revenues in Q1

        AngioDynamics' (ANGO) adjusted gross margin decreased year over year owing to voluntary market withdrawal of the Acculis Microwave Tissue Ablation System.

          Can AngioDynamics (ANGO) Spring a Surprise in Q1 Earnings?

          AngioDynamics (ANGO) is set to report first-quarter fiscal 2018 (ending Aug 31, 2017) results on Sep 28.

            AngioDynamics' BioFlo Platform Strong, Debt Levels High

            AngioDynamics' (ANGO) exclusive Endexo technology in the BioFlo unit is expected to enhance the company's growth trajectory. However, high debt levels limit the company's core business strategies.

              AngioDynamics (ANGO) Up 10.8% Since Earnings Report: Can It Continue?

              AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                AngioDynamics (ANGO) Shares Down Despite Q4 Earnings Beat

                AngioDynamics (ANGO) revenues declined year over year in the fourth quarter. Recall of the Acculis product line under the oncology segment is also a concern.

                  AngioDynamics (ANGO) Down 11.7% Since Earnings Report: Can It Rebound?

                  AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    AngioDynamics (ANGO) Prices 2.5M Secondary Share Offering

                    AngioDynamics, Inc. (ANGO) announced that it has priced its underwritten public offering of 2.35 million shares of common stock.

                      5 Cheap Value Stocks to Tame a Capricious Market in Q2

                      Given the volatile backdrop in the U.S. investment markets, we take a look at five companies which are great value bargains and poised for stellar gains in the second quarter that has just begun.

                        AngioDynamics (ANGO) Beats on Q3 Earnings, Raises 2017 View

                        AngioDynamics Inc. (ANGO), a leading provider of minimally invasive medical devices, reported adjusted earnings of 19 cents per share in the third quarter of fiscal 2017.

                          Here's Why You Should Steer Clear of Mednax (MD) for Now

                          Over the past 6 six months, shares of Mednax (MD) have gained 4.9%., underperforming the 9.8% increase logged by the Zacks categorized Medical - Hospital industry.

                            AngioDynamics Microwave Tissue Ablation System Now CE Marked

                            AngioDynamics Inc. (ANGO), a leading provider of minimally invasive medical devices, recently announced the receipt of CE mark for Solero Microwave Tissue Ablation (MTA) System.

                              AngioDynamics (ANGO) Beats Q2 Earnings, Lifts 2017 View

                              AngioDynamics Inc. (ANGO) reported adjusted earnings of 19 cents per share in the second quarter of fiscal 2017 beating the Zacks Consensus Estimate by 3 cents.

                                Zacks.com featured highlights: First American Financial, AngioDynamics, Microsemi, Thermo Fisher Scientific and F5 Networks

                                Zacks.com featured highlights: First American Financial, AngioDynamics, Microsemi, Thermo Fisher Scientific and F5 Networks

                                  The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, Arch Capital Group, IPG Photonics, AngioDynamics and Express Scripts Holding

                                  The Zacks Analyst Blog Highlights: Thermo Fisher Scientific, Arch Capital Group, IPG Photonics, AngioDynamics and Express Scripts Holding

                                    Tirthankar Chakraborty headshot

                                    New Strong Buy Stocks for November 3rd

                                    Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

                                      Tirthankar Chakraborty headshot

                                      New Strong Buy Stocks for November 1st

                                      Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

                                        Tirthankar Chakraborty headshot

                                        New Strong Buy Stocks for October 19th

                                        Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

                                          Kevin Matras headshot

                                          What's Your Stock's Price Target?

                                          Kevin Matras explains how to calculate a stock's price target and how to find stocks currently trading below them. Highlighted stocks include MTOR, LEN, RFMD, FFIV and ANGO.